ADB-FUBINACA

ADB-FUBINACA

Systematic (IUPAC) name
N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide
Clinical data
Legal status	CA: Schedule II
Identifiers
CAS Number	1445583-51-6 Y
PubChem	CID: 70969086
ChemSpider	29763706
Chemical data
Formula	C21H23FN4O2
Molecular mass	382.43 g/mol
SMILES O=C(NC(C(N)=O)C(C)(C)C)C1=NN(CC2=CC=C(F)C=C2)C3=C1C=CC=C3
InChI InChI=1S/C21H23FN4O2/c1-21(2,3)18(19(23)27)24-20(28)17-15-6-4-5-7-16(15)26(25-17)12-13-8-10-14(22)11-9-13/h4-11,18H,12H2,1-3H3,(H2,23,27)(H,24,28) Key:ZSSGCSINPVBLQD-UHFFFAOYSA-N

ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013. The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982 and has been reported to be a potent agonist of the CB₁ receptor and CB₂ receptor with an EC₅₀ value of 1.2 nM and 3.5 nM respectively. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a tert-butyl group.

An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported.

Side effects

One death through coronary arterial thrombosis has been linked to ADB-FUBINACA intoxication.

See also

• 5F-AB-PINACA
• 5F-ADB
• 5F-AMB
• 5F-APINACA
• AB-CHFUPYCA
• AB-PINACA
• ADB-CHMINACA
• ADB-PINACA
• ADBICA
• ADSB-FUB-187
• APINACA
• MDMB-CHMICA
• MDMB-FUBINACA
• PF-03550096
• PX-3